Narrative Bio

Dr. Avgerinos graduated from the Aristotle University School of Medicine, Thessaloniki, Greece. After serving for several years in the Hellenic Air Force as a Medical Officer, he completed a Master’s in Medical Research Methodology and then joined the National Institute on Aging of NIH, in Baltimore, as a Post-Doctoral Fellow. At the NIH, Dr. Avgerinos designed and conducted pilot clinical trials on novel metabolic interventions in individuals at risk for Alzheimer’s disease, investigating biomarkers of brain metabolism and cognition. He was selected as a Scholar of the Office of Dietary Supplements of NIH (ODS/NIH) and acquired funding to design and conduct a clinical trial on the effects of the ketogenic supplement ketone ester on cognition and brain metabolism. He additionally studied the brain effects of the anti-diabetic medication empagliflozin in humans receiving the NIH Fellows Award for Research Excellence (FARE).

Office Address

Wayne State University School of Medicine
Department of Neurology - 8D UHC
4201 St. Antoine
Detroit, MI 48201
Office Phone: (313) 577-1245
Clinic appointments: (313) 745-4275

Academic Rank

 PGY 2 Resident in Neurology 

Other Information

 Email: konstantinos.avgerinos@wayne.edu

Medical

Medical Degree: Aristotle University School of Medicine, Greece

Master's Degree (Medical Research Methodology): Aristotle University School of Medicine, Greece

Prior Appointments

Post-doctoral Visiting Fellow: National Institute on Aging, NIH

Medical Officer: 251 Air Force General Hospital, Greece 

Publications

Selected 

1. Avgerinos KI, Mullins RJ, Vreones M, Mustapic M, Chen Q, Melvin D, Kapogiannis D, Egan JM. Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics. Cells. 2022; 11(21):3372. https://doi.org/10.3390/cells11213372

2. Avgerinos K.I., Mullins R.J., Egan J.M., Kapogiannis D. Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults ≥ 55 Years Old. A Study Protocol for a Double-Blinded Randomized Controlled Clinical Trial. J Prev Alzheimers Dis (2022). https://doi.org/10.14283/jpad.2022.3

3. Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. Ageing research reviews. 2021;68:101339.

4. Avgerinos KI, Egan JM, Mattson MP, Kapogiannis D. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies. Ageing research reviews. 2020;58:101001.

5. Avgerinos KI, Chatzisotiriou A, Haidich AB, Tsapas A, Lioutas VA. Intravenous Magnesium Sulfate in Acute Stroke. Stroke. 2019;50(4):931-8.

 

← Return to listing